Optic IconOptic Logo
|
SearchCollectionsBenchmarks

Dato-DXd

1 clinical trial

1 product

12 abstracts

1 indication

1 target

Indication
Metastatic Non-small Cell Lung Cancer
Target
TOP1
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.
Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Clinical trial
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
Status: Not yet recruiting, Estimated PCD: 2026-09-08
Abstract
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.
Org: Gustave Roussy Cancer Center, Biostatistics Unit, Hopital Cochin, Chi Creteil, Centre François Baclesse,
Abstract
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
Org: Sarah Cannon Research Institute/Tennessee Oncology, Jilin Cancer Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Beijing Cancer Hospital,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).
Org: University Hospital of Nantes Medical Oncology,
Abstract
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
Org: Winship Cancer Institute of Emory University, Atlanta, GA, University of Alabama at Birmingham, Birmingham, AL, University of California, San Francisco, San Francisco, CA, University of California, San Diego, La Jolla, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.
Org: CNIO-H12O Lung Cancer Unit, Departamento de Investigacion de Cancer de Pulmon, Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Department of Oncology, National Cheng Kung University Hospital, Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Università degli Studi di Milano-Bicocca,
Abstract
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.
Org: National Cancer Center East, Daiichi Sankyo Ltd.,
Abstract
Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.
Org: Jiangxi Provincial People's Hospital,
Abstract
Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05.
Org: University Hospital of Nantes, Daiichi Sankyo Europe GmbH, Department of Medical Oncology, Thoracic Group,
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, University of Wisconsin Carbone Cancer Center,
Product
Datopotamab